NL1006681C2 - Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. - Google Patents

Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. Download PDF

Info

Publication number: NL1006681C2
Authority: NL; Netherlands
Prior art keywords: tissue; use according; damage; vanadium; traumatic event
Prior art date: 1997-07-29

Application number

NL1006681A

Other languages

English (en)

Dutch (nl)

Inventor

Conradus Ghosal Gho

Original Assignee

Gho St Holding Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-29

Filing date

1997-07-29

Publication date

1999-02-08

1997-07-29 Priority to NL1006681A priority Critical patent/NL1006681C2/nl

1997-07-29 Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv

1998-07-29 Priority to CA002298645A priority patent/CA2298645C/en

1998-07-29 Priority to NZ502613A priority patent/NZ502613A/en

1998-07-29 Priority to ES98937862T priority patent/ES2207851T3/es

1998-07-29 Priority to EA200000176A priority patent/EA002574B1/ru

1998-07-29 Priority to EP98937862A priority patent/EP1001792B1/en

1998-07-29 Priority to IL13425998A priority patent/IL134259A0/xx

1998-07-29 Priority to CN98809293A priority patent/CN1104244C/zh

1998-07-29 Priority to PL98338415A priority patent/PL338415A1/xx

1998-07-29 Priority to DK98937862T priority patent/DK1001792T3/da

1998-07-29 Priority to AT98937862T priority patent/ATE253373T1/de

1998-07-29 Priority to JP2000504869A priority patent/JP2001511454A/ja

1998-07-29 Priority to DE69819514T priority patent/DE69819514T2/de

1998-07-29 Priority to IDW20000183A priority patent/ID24870A/id

1998-07-29 Priority to US09/463,697 priority patent/US6579540B1/en

1998-07-29 Priority to BR9811298-8A priority patent/BR9811298A/pt

1998-07-29 Priority to PT98937862T priority patent/PT1001792E/pt

1998-07-29 Priority to TR2000/00349T priority patent/TR200000349T2/xx

1998-07-29 Priority to PCT/NL1998/000431 priority patent/WO1999006056A1/en

1998-07-29 Priority to AU86505/98A priority patent/AU738701B2/en

1998-07-29 Priority to CZ20000326A priority patent/CZ299716B6/cs

1999-02-08 Application granted granted Critical

1999-02-08 Publication of NL1006681C2 publication Critical patent/NL1006681C2/nl

2000-01-27 Priority to IL134259A priority patent/IL134259A/en

2000-01-28 Priority to NO20000446A priority patent/NO20000446L/no

2003-04-21 Priority to US10/419,914 priority patent/US20030211170A1/en

Links

150000003682 vanadium compounds Chemical class 0.000 title claims abstract description 44
150000003839 salts Chemical class 0.000 title claims abstract description 19
230000006378 damage Effects 0.000 claims abstract description 65
230000000472 traumatic effect Effects 0.000 claims abstract description 19
210000001519 tissue Anatomy 0.000 claims description 75
230000002062 proliferating effect Effects 0.000 claims description 23
208000028867 ischemia Diseases 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 7
238000001356 surgical procedure Methods 0.000 claims description 7
230000002792 vascular Effects 0.000 claims description 6
XUOLEICXAPEOSI-UHFFFAOYSA-L 2-methyl-4-oxopyran-3-olate;oxovanadium(2+) Chemical compound [V+2]=O.CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] XUOLEICXAPEOSI-UHFFFAOYSA-L 0.000 claims description 5
210000004209 hair Anatomy 0.000 claims description 5
210000002216 heart Anatomy 0.000 claims description 5
210000001732 sebaceous gland Anatomy 0.000 claims description 4
210000000106 sweat gland Anatomy 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
210000005036 nerve Anatomy 0.000 claims description 2
239000008196 pharmacological composition Substances 0.000 claims 4
208000027418 Wounds and injury Diseases 0.000 abstract description 11
208000014674 injury Diseases 0.000 abstract description 5
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 3
238000011321 prophylaxis Methods 0.000 abstract description 3
238000011282 treatment Methods 0.000 description 16
210000003491 skin Anatomy 0.000 description 15
230000006907 apoptotic process Effects 0.000 description 13
241000282898 Sus scrofa Species 0.000 description 12
239000003102 growth factor Substances 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
206010052428 Wound Diseases 0.000 description 8
230000000694 effects Effects 0.000 description 8
229910052720 vanadium Inorganic materials 0.000 description 8
LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical group [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 8
102000014429 Insulin-like growth factor Human genes 0.000 description 7
230000035876 healing Effects 0.000 description 7
210000005003 heart tissue Anatomy 0.000 description 7
230000010410 reperfusion Effects 0.000 description 7
XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
150000003681 vanadium Chemical class 0.000 description 6
241000282412 Homo Species 0.000 description 5
241000282887 Suidae Species 0.000 description 5
210000005013 brain tissue Anatomy 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
210000004207 dermis Anatomy 0.000 description 4
210000002615 epidermis Anatomy 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
230000002107 myocardial effect Effects 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
206010011086 Coronary artery occlusion Diseases 0.000 description 3
102000009024 Epidermal Growth Factor Human genes 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
102000043136 MAP kinase family Human genes 0.000 description 3
108091054455 MAP kinase family Proteins 0.000 description 3
HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000008602 contraction Effects 0.000 description 3
230000030609 dephosphorylation Effects 0.000 description 3
238000006209 dephosphorylation reaction Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229940043353 maltol Drugs 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
230000008569 process Effects 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
239000000021 stimulant Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 3
229910000352 vanadyl sulfate Inorganic materials 0.000 description 3
102000005862 Angiotensin II Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229950006323 angiotensin ii Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
229960004705 kojic acid Drugs 0.000 description 2
WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 2
125000005287 vanadyl group Chemical group 0.000 description 2
229940041260 vanadyl sulfate Drugs 0.000 description 2
238000005303 weighing Methods 0.000 description 2
FETLPNKZRXDWLT-UHFFFAOYSA-N 2-(4,5-dihydro-1,3-oxazol-2-yl)phenol Chemical class OC1=CC=CC=C1C1=NCCO1 FETLPNKZRXDWLT-UHFFFAOYSA-N 0.000 description 1
WAPGIVPBBDUIRS-UHFFFAOYSA-N 2-(4,5-dihydro-1,3-thiazol-2-yl)phenol Chemical class OC1=CC=CC=C1C1=NCCS1 WAPGIVPBBDUIRS-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
102000008873 Angiotensin II receptor Human genes 0.000 description 1
108050000824 Angiotensin II receptor Proteins 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
208000023514 Barrett esophagus Diseases 0.000 description 1
206010006802 Burns second degree Diseases 0.000 description 1
206010006803 Burns third degree Diseases 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
CFVBFMMHFBHNPZ-UHFFFAOYSA-N [Na].[V] Chemical compound [Na].[V] CFVBFMMHFBHNPZ-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
210000000040 apocrine gland Anatomy 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000004177 elastic tissue Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000003499 exocrine gland Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
230000010005 growth-factor like effect Effects 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000005184 irreversible process Methods 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
231100000149 liver necrosis Toxicity 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000013178 mathematical model Methods 0.000 description 1
230000006996 mental state Effects 0.000 description 1
244000309715 mini pig Species 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000037387 scars Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229910001456 vanadium ion Inorganic materials 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Surgery (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

NL1006681A 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. NL1006681C2 (nl)

Priority Applications (24)

Application Number	Priority Date	Filing Date	Title
NL1006681A NL1006681C2 (nl)	1997-07-29	1997-07-29	Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
IDW20000183A ID24870A (id)	1997-07-29	1998-07-29	Penggunaan senyawa vanadium, garam dan kompleksnya yang dapat diterima secara fisiologi
ES98937862T ES2207851T3 (es)	1997-07-29	1998-07-29	Uso de compuestos, sales o complejos de vanadio fisiologicamente aceptables.
EA200000176A EA002574B1 (ru)	1997-07-29	1998-07-29	Применение физиологически приемлемых соединений, солей и комплексов ванадия
EP98937862A EP1001792B1 (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds, salts and complexes
IL13425998A IL134259A0 (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds, salts and complexes
CN98809293A CN1104244C (zh)	1997-07-29	1998-07-29	生理学上可接受的钒化合物、盐和配合物的应用
PL98338415A PL338415A1 (en)	1997-07-29	1998-07-29	Application of physiologically compatible vanadium compounds, salts and complexes
DK98937862T DK1001792T3 (da)	1997-07-29	1998-07-29	Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
AT98937862T ATE253373T1 (de)	1997-07-29	1998-07-29	Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen
CA002298645A CA2298645C (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds, salts and complexes
DE69819514T DE69819514T2 (de)	1997-07-29	1998-07-29	Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen
BR9811298-8A BR9811298A (pt)	1997-07-29	1998-07-29	Uso de um composto de vanádio fisiologicamente aceitável
JP2000504869A JP2001511454A (ja)	1997-07-29	1998-07-29	生理学的に受容可能なバナジウム化合物，塩および複合体
CZ20000326A CZ299716B6 (cs)	1997-07-29	1998-07-29	Použití fyziologicky prijatelné vanadové slouceniny
PT98937862T PT1001792E (pt)	1997-07-29	1998-07-29	Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
TR2000/00349T TR200000349T2 (tr)	1997-07-29	1998-07-29	Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.
PCT/NL1998/000431 WO1999006056A1 (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds, salts and complexes
AU86505/98A AU738701B2 (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds, salts and complexes
NZ502613A NZ502613A (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds for the prophylactic treatment of secondary injury of tissue
US09/463,697 US6579540B1 (en)	1997-07-29	1998-07-29	Use of physiologically acceptable vanadium compounds, salts and complexes
IL134259A IL134259A (en)	1997-07-29	2000-01-27	Use of physiologically acceptable vanadium compounds, salts and complexes in the preparation of pharmaceutical compositions
NO20000446A NO20000446L (no)	1997-07-29	2000-01-28	Anvendelse av fysiologisk akseptable vanadiumforbindelser, - salter og -komplekser
US10/419,914 US20030211170A1 (en)	1997-07-29	2003-04-21	Use of physiologically acceptable vanadium compounds, salts and complexes

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL1006681		1997-07-29
NL1006681A NL1006681C2 (nl)	1997-07-29	1997-07-29	Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Publications (1)

Publication Number	Publication Date
NL1006681C2 true NL1006681C2 (nl)	1999-02-08

Family

ID=19765422

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL1006681A NL1006681C2 (nl)	1997-07-29	1997-07-29	Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Country Status (22)

Country	Link
US (2)	US6579540B1 (id)
EP (1)	EP1001792B1 (id)
JP (1)	JP2001511454A (id)
CN (1)	CN1104244C (id)
AT (1)	ATE253373T1 (id)
AU (1)	AU738701B2 (id)
BR (1)	BR9811298A (id)
CA (1)	CA2298645C (id)
CZ (1)	CZ299716B6 (id)
DE (1)	DE69819514T2 (id)
DK (1)	DK1001792T3 (id)
EA (1)	EA002574B1 (id)
ES (1)	ES2207851T3 (id)
ID (1)	ID24870A (id)
IL (2)	IL134259A0 (id)
NL (1)	NL1006681C2 (id)
NO (1)	NO20000446L (id)
NZ (1)	NZ502613A (id)
PL (1)	PL338415A1 (id)
PT (1)	PT1001792E (id)
TR (1)	TR200000349T2 (id)
WO (1)	WO1999006056A1 (id)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL1006681C2 (nl) *	1997-07-29	1999-02-08	Gho St Holding Bv	Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) *	1998-02-10	2012-06-05	Angros Lee H	Method of applying a biological specimen to an analytic plate
WO2001045716A1 (en) *	1999-12-20	2001-06-28	Gho'st Holding B.V.	Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor
WO2003041703A2 (en) *	2001-11-16	2003-05-22	Gho Holding B.V.	Use of a flavonoid for the treatment of burns
BRPI0807047A2 (pt)	2007-01-31	2014-04-22	Basf Plant Science Gmbh	Método para o aumento da resistência ao estresse abiótico em plantas relativa as plantas de controle, e, usos de uma construção, e de um ácido nucleico que codifica um polipeptídeo semelhante a nap1.
EP2230310B1 (en)	2007-05-03	2013-01-16	BASF Plant Science GmbH	Plants having enhanced yield-related traits and a method for making the same
AR067633A1 (es)	2007-07-20	2009-10-21	Basf Plant Science Gmbh	Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para producirlas
AR067748A1 (es)	2007-07-31	2009-10-21	Basf Plant Science Gmbh	Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
CA2703827A1 (en)	2007-10-29	2009-05-07	Basf Plant Science Gmbh	Plants having enhanced yield-related traits and a method for making the same
DE112009000934T5 (de)	2008-05-05	2011-07-14	BASF Plant Science GmbH, 67063	Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu ihrer Herstellung
US20100078320A1 (en) *	2008-09-26	2010-04-01	Applied Materials, Inc.	Microwave plasma containment shield shaping
EP2523672B1 (en)	2010-01-15	2016-07-13	Rutgers, the State University of New Jersey	Use of vanadium compounds to accelerate bone healing
US20140322292A1 (en)	2010-12-10	2014-10-30	Rutgers, The State University Of New Jersey	Insulin-mimetics as therapeutic adjuncts for bone regeneration
CN103781358A (zh)	2010-12-10	2014-05-07	新泽西医科和牙科大学	涂布有胰岛素模拟剂复合材料的可植入装置及其方法
RU2017122329A (ru) *	2011-03-07	2019-01-30	СиЭфЭм ФАРМА ХОЛДИНГ БВ	Применение соединений ванадия для поддержания нормогликемии у млекопитающего
US9931348B2 (en) *	2011-07-06	2018-04-03	Rutgers, The State University Of New Jersey	Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl)	2012-11-07	2019-01-31	Univ Jagiellonski	Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2010222C2 (en) *	2013-02-01	2014-08-04	Conradus Ghosal Gho	Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
NL2019605B1 (en) *	2017-09-22	2019-03-28	Cfm Pharma Holding B V	Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990012563A1 (en) *	1989-04-24	1990-11-01	Board Of Regents, The University Of Texas System	Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
WO1996023811A1 (fr) *	1995-01-31	1996-08-08	Maurel Sante	Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5565491A (en) *	1994-01-31	1996-10-15	Bristol-Myers Squibb Company	Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
NL1006681C2 (nl) *	1997-07-29	1999-02-08	Gho St Holding Bv	Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

1997
- 1997-07-29 NL NL1006681A patent/NL1006681C2/nl not_active IP Right Cessation
1998
- 1998-07-29 DE DE69819514T patent/DE69819514T2/de not_active Expired - Lifetime
- 1998-07-29 JP JP2000504869A patent/JP2001511454A/ja active Pending
- 1998-07-29 NZ NZ502613A patent/NZ502613A/en not_active IP Right Cessation
- 1998-07-29 EP EP98937862A patent/EP1001792B1/en not_active Expired - Lifetime
- 1998-07-29 US US09/463,697 patent/US6579540B1/en not_active Expired - Lifetime
- 1998-07-29 EA EA200000176A patent/EA002574B1/ru not_active IP Right Cessation
- 1998-07-29 AU AU86505/98A patent/AU738701B2/en not_active Ceased
- 1998-07-29 PL PL98338415A patent/PL338415A1/xx unknown
- 1998-07-29 AT AT98937862T patent/ATE253373T1/de not_active IP Right Cessation
- 1998-07-29 ES ES98937862T patent/ES2207851T3/es not_active Expired - Lifetime
- 1998-07-29 CZ CZ20000326A patent/CZ299716B6/cs not_active IP Right Cessation
- 1998-07-29 WO PCT/NL1998/000431 patent/WO1999006056A1/en not_active Ceased
- 1998-07-29 TR TR2000/00349T patent/TR200000349T2/xx unknown
- 1998-07-29 ID IDW20000183A patent/ID24870A/id unknown
- 1998-07-29 CA CA002298645A patent/CA2298645C/en not_active Expired - Fee Related
- 1998-07-29 BR BR9811298-8A patent/BR9811298A/pt not_active Application Discontinuation
- 1998-07-29 CN CN98809293A patent/CN1104244C/zh not_active Expired - Fee Related
- 1998-07-29 DK DK98937862T patent/DK1001792T3/da active
- 1998-07-29 IL IL13425998A patent/IL134259A0/xx unknown
- 1998-07-29 PT PT98937862T patent/PT1001792E/pt unknown
2000
- 2000-01-27 IL IL134259A patent/IL134259A/en not_active IP Right Cessation
- 2000-01-28 NO NO20000446A patent/NO20000446L/no not_active Application Discontinuation
2003
- 2003-04-21 US US10/419,914 patent/US20030211170A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990012563A1 (en) *	1989-04-24	1990-11-01	Board Of Regents, The University Of Texas System	Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
WO1996023811A1 (fr) *	1995-01-31	1996-08-08	Maurel Sante	Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ODEKON L E ET AL: "UROKINASE-TYPE PLASMINOGEN ACTIVATOR MEDIATES BASIC FIBROBLAST GROWTH FACTOR-INDUCED BOVINE ENDOTHELIAL CELL MIGRATION INDEPENDENT OF ITS PROTEOLYTIC ACTIVITY", J CELL PHYSIOL, 150 (2). 1992. 258-263., XP002059979 *

Also Published As

Publication number	Publication date
NO20000446D0 (no)	2000-01-28
CN1104244C (zh)	2003-04-02
ATE253373T1 (de)	2003-11-15
PT1001792E (pt)	2004-03-31
NZ502613A (en)	2001-08-31
EP1001792B1 (en)	2003-11-05
ID24870A (id)	2000-08-31
EA002574B1 (ru)	2002-06-27
IL134259A (en)	2010-02-17
PL338415A1 (en)	2000-11-06
AU8650598A (en)	1999-02-22
CA2298645A1 (en)	1999-02-11
AU738701B2 (en)	2001-09-27
CZ299716B6 (cs)	2008-10-29
EP1001792A1 (en)	2000-05-24
US6579540B1 (en)	2003-06-17
CN1270525A (zh)	2000-10-18
CA2298645C (en)	2004-05-18
WO1999006056A1 (en)	1999-02-11
ES2207851T3 (es)	2004-06-01
BR9811298A (pt)	2000-08-29
JP2001511454A (ja)	2001-08-14
DE69819514D1 (de)	2003-12-11
CZ2000326A3 (cs)	2000-07-12
TR200000349T2 (tr)	2000-09-21
EA200000176A1 (ru)	2000-10-30
NO20000446L (no)	2000-03-24
IL134259A0 (en)	2001-04-30
DK1001792T3 (da)	2004-01-19
US20030211170A1 (en)	2003-11-13
DE69819514T2 (de)	2004-09-23

Legal Events

Date	Code	Title	Description
1999-04-01	PD2B	A search report has been drawn up
2005-04-01	VD1	Lapsed due to non-payment of the annual fee	Effective date: 20050201

Publication	Publication Date	Title
US6579540B1 (en)	2003-06-17	Use of physiologically acceptable vanadium compounds, salts and complexes
Luly et al.	1972	Hormonal control in vitro of plasma membrane-bound (Na+− K+)-ATPase of rat liver
EP0655460B1 (de)	2000-01-19	Pharmazeutisch therapeutische Verwendung von Glutathion-Derivaten
HU206988B (en)	1993-03-01	Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient
JP2009513682A (ja)	2009-04-02	相乗的効果を奏する割合でγ−及びα−インターフェロンを含有する安定化製剤
CN116726021B (zh)	2024-10-29	一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
US20200277602A1 (en)	2020-09-03	Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
NL7909199A (nl)	1980-06-24	Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan.
Wang et al.	2012	Effects of sildenafil and/or muscle derived stem cells on myocardial infarction
Cameron et al.	1977	Total intravenous hyperalimentation and hydroxyurea chemotherapy in hepatoma-bearing rats
Tiron et al.	2023	White rats’ thyroid gland morphological changes throughout the experimental thermal injury in conditions of lactoprotein with sorbitol hyperosmolar solutions administration
CA2304956C (en)	2013-12-03	Pharmaceutical composition for preventing or treating ischemic diseases
JPS63501219A (ja)	1988-05-12	内分泌系ホルモン生成抑制用非経口投与治療組成物および方法
US20030108620A1 (en)	2003-06-12	Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a na+/hinhibitors, cyclo-oxygenase inhibitors and caspase inhibitors
NL9300065A (nl)	1993-08-16	Samenstelling voor het versnellen van wondgenezing.
MXPA00001037A (en)	2001-12-04	Use of physiologically acceptable vanadium compounds, salts and complexes
JPH0296535A (ja)	1990-04-09	骨髄機能障害性貧血治療剤
NZ519631A (en)	2004-06-25	Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a Na+/H+ exchanger inhibitors, cyclo-oxygenase inhibitors and caspase inhibitors
RU2146927C1 (ru)	2000-03-27	Препарат для лечения рака кожи и предраковых заболеваний кожи
CN115634220A (zh)	2023-01-24	二甲双胍在制备预防和/或治疗电磁辐射致生殖损伤的产品中的应用
KR19980020379A (ko)	1998-06-25	사이토킨 성장인자로 인한 질병의 치료방법
Shafiroff et al.	1951	Subcutaneous administration of combined fat emulsion with hyaluronidase.
JPH0272123A (ja)	1990-03-12	ヒト上皮細胞成長因子の投与方法及びヒト上皮細胞成長因子含有疾病治療剤